Oncology

A new systematic review sheds light on how prehabilitation, interventions initiated before treatment, may influence long-term physical function and patient-reported outcomes in people affected by bladder cancer.

In the treatment of relapsed/refractory multiple myeloma, CAR T-cell therapy using idecabtagene vicleucel (ide-cel) has demonstrated encouraging results in a large real-world U.S. patient cohort, according to new data from the CIBMTR registry.

A new study on superficial basal cell carcinoma treatment decisions highlights that patient decision aids may subtly shift treatment preferences, with keywords such as superficial basal cell carcinoma, patient decision aid, non-invasive treatment, and effective decision-making underscoring the research.

A major phase 3 lung cancer trial investigating the TGIT-targeting immunotherapy ociperlimab has been halted after interim analysis indicated it would not meet its primary endpoint of overall survival.

The rapid rise in prescriptions for GLP-1 receptor agonists, including tirzepatide (Mounjaro) and semaglutide (Ozempic; Lilly, Indianapolis, Indiana, USA), has sparked concerns about potential long-term safety risks.

Transportation barriers are a significant yet often overlooked challenge for patients with multiple myeloma (MM), affecting access to timely care and overall health outcomes.

Virtual reality (VR) is emerging as a powerful tool for enhancing cancer patient education, significantly improving understanding of disease and treatment, according to new research.

Discover how SITC’s innovative strategies are transforming clinical trials to accelerate the development and approval of cancer immunotherapies, aiming for 100 new treatments in the next decade.